首页 | 本学科首页   官方微博 | 高级检索  
     


Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
Authors:P. Chowdary  S. Lethagen  U. Friedrich  B. Brand  C. Hay  F. Abdul Karim  R. Klamroth  P. Knoebl  M. Laffan  J. Mahlangu  W. Miesbach  J. Dalsgaard Nielsen  M. Martín‐Salces  P. Angchaisuksiri
Affiliation:1. Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, UK;2. Novo Nordisk A/S, S?borg, Denmark;3. Copenhagen University, Copenhagen, Denmark;4. Division of Hematology, University Hospital, Zurich, Switzerland;5. University Department of Haematology, Manchester Royal Infirmary, Manchester, UK;6. Haemophilia Centre, National Blood Centre, Kuala Lumpur, Malaysia;7. Department of Internal Medicine―Angiology, Haemostasis and Coagulation disorders, Vivantes Hospital im Friedrichshain, Berlin, Germany;8. Division of Haematology and Haemostasis, Department of Medicine 1, Medical University of Vienna, Vienna, Austria;9. Imperial College London, Hammersmith Hospital, London, UK;10. Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa;11. Zentrum für Innere Medizin, Med. Klinik III, H?mophilie‐Zentrum, Frankfurt/M, Germany;12. Thrombosis and Haemostasis Unit, Department of Haematology, Rigshospitalet, Copenhagen, Denmark;13. Haematology Department, Hospital Universitario La Paz, Madrid, Spain;14. Division of Hematology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand
Abstract:
Keywords:hemophilia  mAb 2021  pharmacokinetics  safety  tissue factor pathway inhibitor
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号